Microsatellite Instability (MSI) is a genomic phenotype characterized by widespread length alterations in short, repetitive DNA sequences (microsatellites) caused by a failure of the DNA mismatch repair (MMR) system to correct replication errors. This hypermutable state generates thousands of somatic mutations, particularly in coding microsatellites, producing neoantigens that make MSI-high tumors highly responsive to immune checkpoint inhibitor therapy.
Glossary
Microsatellite Instability (MSI)
A genomic phenotype of hypermutation caused by defective DNA mismatch repair, identified computationally from sequencing data as a pan-cancer biomarker for immunotherapy eligibility.
GENOMIC BIOMARKER
What is Microsatellite Instability (MSI)?
A hypermutable phenotype arising from defective DNA mismatch repair, computationally identified to guide immunotherapy decisions.
Computationally, MSI status is determined from next-generation sequencing data by assessing indel distributions across a panel of mononucleotide repeat loci, bypassing traditional immunohistochemistry. Algorithms like MSIsensor and MANTIS quantify instability by comparing the allelic length profiles of tumor and normal samples, classifying tumors as MSI-High (MSI-H) or microsatellite stable (MSS) as a pan-cancer biomarker for pembrolizumab eligibility.
PHENOTYPIC HALLMARKS
Key Characteristics of MSI Tumors
Microsatellite instability produces a distinct set of genomic and histopathological features that distinguish MSI-high tumors from microsatellite-stable malignancies, enabling computational identification from both sequencing data and whole-slide images.
01
Hypermutation Phenotype
MSI-H tumors accumulate orders of magnitude more somatic mutations than microsatellite-stable (MSS) tumors due to defective mismatch repair (dMMR). Tumor Mutational Burden (TMB) frequently exceeds 10-50 mutations per megabase, generating abundant neoantigens that trigger immune recognition. This hypermutation is not uniform—it concentrates in repetitive microsatellite loci where polymerase slippage errors go uncorrected during DNA replication.
10-50+
Mutations per Megabase
100x+
Mutation Rate vs. MSS
02
Lymphocytic Infiltration
MSI-H tumors exhibit dense immune cell infiltration, particularly tumor-infiltrating lymphocytes (TILs) and peritumoral lymphoid aggregates. This immune-rich microenvironment results from the high neoantigen load stimulating a robust anti-tumor immune response. Key histological features include:
- Intraepithelial TILs within tumor cell nests
- Crohn's-like lymphoid reaction at the invasive margin
- Tertiary lymphoid structures with organized B and T cell zones
2-5x
TIL Density vs. MSS
03
Frameshift Neoantigens
Insertion/deletion errors in coding microsatellites cause frameshift mutations that generate aberrant protein sequences downstream. These frameshift peptides are translated into highly immunogenic neoantigens presented on MHC class I molecules. Recurrent frameshift targets include TGFBR2, BAX, MSH3, and ACVR2—genes harboring mononucleotide repeats in their coding regions that act as bystander mutation hotspots during dMMR-driven tumorigenesis.
05
Checkpoint Inhibitor Sensitivity
The high neoantigen burden and pre-existing immune infiltration make MSI-H tumors exquisitely responsive to immune checkpoint blockade targeting PD-1/PD-L1 and CTLA-4. This led to the first tissue-agnostic FDA approval of pembrolizumab for any MSI-H/dMMR solid tumor in 2017. Response rates exceed 40-50% even in heavily pre-treated patients, with durable complete responses observed across colorectal, endometrial, gastric, and other cancer types.
40-50%
Objective Response Rate
Tissue-Agnostic
FDA Approval Type
06
Pan-Cancer Prevalence
MSI-H occurs across multiple cancer types with highly variable prevalence. Colorectal and endometrial cancers show the highest rates (15-20%), while other solid tumors exhibit lower frequencies. Lynch syndrome-associated cancers universally display MSI-H, but sporadic MLH1 promoter hypermethylation accounts for the majority of cases. Key prevalence rates:
- Colorectal adenocarcinoma: 15%
- Endometrial carcinoma: 20-30%
- Gastric adenocarcinoma: 8-22%
- Ovarian carcinoma: 10-12%
15-30%
Endometrial Prevalence
39
Cancer Types with MSI-H
BIOMARKER COMPARISON
MSI vs. Tumor Mutational Burden (TMB)
Comparative analysis of two genomic biomarkers used to predict immunotherapy response, derived from distinct biological mechanisms.
| Feature | Microsatellite Instability (MSI) | Tumor Mutational Burden (TMB) | Overlap / Notes |
|---|---|---|---|
Biological Mechanism | Defective mismatch repair (dMMR) causing slippage errors in repetitive DNA tracts | Total somatic mutations per megabase of coding genome, regardless of cause | dMMR is one cause of high TMB; not all high-TMB tumors are MSI-H |
Measurement Method | PCR of Bethesda panel or NGS assessing instability at microsatellite loci | Whole-exome or targeted NGS panel counting non-synonymous mutations | NGS panels can compute both simultaneously |
Unit of Measurement | Categorical: MSI-H, MSI-L, or MSS | Continuous: mutations per megabase (mut/Mb) | MSI-H tumors typically have TMB > 10 mut/Mb |
Tissue Types with Highest Prevalence | Colorectal, endometrial, gastric | Melanoma, NSCLC, bladder (UV/smoking-driven) | MSI-H is rare in melanoma; TMB-H is common |
FDA-Approved Companion Diagnostic | Yes (pembrolizumab for MSI-H solid tumors, tissue-agnostic) | Yes (pembrolizumab for TMB-H ≥ 10 mut/Mb solid tumors) | MSI-H approval predates TMB-H; both are pan-cancer |
Key Computational Tools | MANTIS, MSIsensor-pro, mSINGS | Mutect2 + annotation pipelines, TMB calculators | Tools differ; concordance studies required for harmonization |
Cutoff for Clinical Actionability | MSI-H by NGS or ≥ 2 unstable markers by PCR | ≥ 10 mut/Mb (FoundationOne CDx threshold) | Thresholds vary by assay; harmonization efforts ongoing |
Predictive Value Independent of TMB | Yes; MSI-H predicts response even at moderate TMB | Yes; TMB-H predicts response even in MSS tumors | Combined assessment may refine patient selection |
MICROSATELLITE INSTABILITY
Frequently Asked Questions
Explore the computational and biological foundations of Microsatellite Instability (MSI), a critical genomic phenotype for guiding immunotherapy decisions in precision oncology.
Microsatellite Instability (MSI) is a genomic phenotype characterized by the accumulation of insertion or deletion mutations in repetitive DNA sequences, known as microsatellites, due to a defective DNA mismatch repair (dMMR) system. These short tandem repeats, typically 1-6 base pairs in length, are prone to polymerase slippage errors during replication. In normal cells, the mismatch repair (MMR) machinery—primarily the proteins MLH1, MSH2, MSH6, and PMS2—corrects these errors. When this system fails, the errors remain uncorrected, leading to length polymorphisms in microsatellite loci across the genome. This hypermutable state generates thousands of somatic mutations, particularly in coding microsatellites of tumor suppressor genes, driving oncogenesis. MSI is a hallmark of Lynch syndrome but also occurs sporadically, most commonly through epigenetic silencing of the MLH1 promoter via hypermethylation. Clinically, MSI status is classified as MSI-High (MSI-H) if instability is detected in two or more of the five Bethesda panel markers, or MSI-Low/Stable if one or none are unstable.
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.
Enterprise searchRAGPermissions
Read more
Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.
AI agentsWorkflow automationGovernance
Read more
Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
AI integrationDecision supportModel routing
Read more
About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
LinkedIn
Limited slotsGet a Free AI Consultation
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us